{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:10:41Z","timestamp":1790831441583,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-RHUS-0012"],"award-info":[{"award-number":["ANR-18-RHUS-0012"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-LABX-0042"],"award-info":[{"award-number":["ANR-11-LABX-0042"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["DQ20170336751"],"award-info":[{"award-number":["DQ20170336751"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"DOI":"10.1007\/s12311-023-01524-6","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T06:03:01Z","timestamp":1675317781000},"page":"181-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model"],"prefix":"10.1007","volume":"23","author":[{"given":"Fabrice","family":"Faure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Yshii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toufic","family":"Renno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"coste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Desestret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Liblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4721-5952","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"1524_CR1","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/brain\/awg133","volume":"126","author":"S Shams\u2019ili","year":"2003","unstructured":"Shams\u2019ili S, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126:1409\u201318.","journal-title":"Brain"},{"key":"1524_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s004010050460","volume":"91","author":"J Verschuuren","year":"1996","unstructured":"Verschuuren J, et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol. 1996;91:519\u201325.","journal-title":"Acta Neuropathol"},{"key":"1524_CR3","doi-asserted-by":"crossref","unstructured":"Yshii L, Bost C, Liblau R. Immunological bases of paraneoplastic cerebellar degeneration and therapeutic implications. Front Immunol. 2020;11:991.","DOI":"10.3389\/fimmu.2020.00991"},{"key":"1524_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0303-8467(95)00005-5","volume":"97","author":"M Tanaka","year":"1995","unstructured":"Tanaka M, Tanaka K, Onodera O, Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin Neurol Neurosurg. 1995;97:95\u2013100.","journal-title":"Clin Neurol Neurosurg"},{"key":"1524_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0303-8467(95)00006-6","volume":"97","author":"K Tanaka","year":"1995","unstructured":"Tanaka K, et al. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg. 1995;97:101\u20135.","journal-title":"Clin Neurol Neurosurg"},{"key":"1524_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaut.2005.01.008","volume":"24","author":"M Saiki","year":"2005","unstructured":"Saiki M, et al. Induction of humoral responses specific for paraneoplastic cerebellar degeneration-associated antigen by whole recombinant yeast immunization. J Autoimmun. 2005;24:203\u20138.","journal-title":"J Autoimmun"},{"key":"1524_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1006\/jaut.2001.0553","volume":"17","author":"K Sakai","year":"2001","unstructured":"Sakai K, Shirakawa T, Kitagawa Y, Li Y, Hirose G. Induction of cytotoxic T lymphocytes specific for paraneoplastic cerebellar degeneration-associated antigen in vivo by DNA immunization. J Autoimmun. 2001;17:297\u2013302.","journal-title":"J Autoimmun"},{"key":"1524_CR8","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/brain\/aww225","volume":"139","author":"LM Yshii","year":"2016","unstructured":"Yshii LM, et al. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain. 2016;139:2923\u201334.","journal-title":"Brain"},{"key":"1524_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nri3108","volume":"11","author":"LSK Walker","year":"2011","unstructured":"Walker LSK, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11:852\u201363.","journal-title":"Nat Rev Immunol"},{"key":"1524_CR10","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1523\/JNEUROSCI.17-04-01406.1997","volume":"17","author":"JP Corradi","year":"1997","unstructured":"Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci. 1997;17:1406\u201315.","journal-title":"J Neurosci"},{"key":"1524_CR11","doi-asserted-by":"crossref","unstructured":"Eichler TW, et al. CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLoS One. 2013;8(6):e66002.","DOI":"10.1371\/journal.pone.0066002"},{"key":"1524_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ana.25511","volume":"86","author":"T Kr\u00e5kenes","year":"2019","unstructured":"Kr\u00e5kenes T, et al. CDR2L is the major Yo antibody target in paraneoplastic cerebellar degeneration. Ann Neurol. 2019;86:316\u201321.","journal-title":"Ann Neurol"},{"key":"1524_CR13","doi-asserted-by":"publisher","first-page":"e1260212","DOI":"10.1080\/2162402X.2016.1260212","volume":"6","author":"C Gebauer","year":"2017","unstructured":"Gebauer C, et al. CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model. OncoImmunology. 2017;6:e1260212.","journal-title":"OncoImmunology"},{"key":"1524_CR14","doi-asserted-by":"publisher","first-page":"e27384","DOI":"10.4161\/onci.27384","volume":"2","author":"BS Pignolet","year":"2013","unstructured":"Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies. OncoImmunology. 2013;2:e27384.","journal-title":"OncoImmunology"},{"key":"1524_CR15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/3315","volume":"4","author":"ML Albert","year":"1998","unstructured":"Albert ML, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med. 1998;4:1321\u20134.","journal-title":"Nat Med"},{"key":"1524_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00401-017-1802-y","volume":"135","author":"M Small","year":"2018","unstructured":"Small M, et al. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol. 2018;135:569\u201379.","journal-title":"Acta Neuropathol"},{"key":"1524_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","volume":"21","author":"KF Roby","year":"2000","unstructured":"Roby KF, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585\u201391.","journal-title":"Carcinogenesis"},{"key":"1524_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0022-1759(03)00081-4","volume":"276","author":"DB Flies","year":"2003","unstructured":"Flies DB, Chen L. A simple and rapid vortex method for preparing antigen\/adjuvant emulsions for immunization. J Immunol Methods. 2003;276:239\u201342.","journal-title":"J Immunol Methods"},{"key":"1524_CR19","doi-asserted-by":"publisher","unstructured":"Liu L, and Duff K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. JoVE. 2008;960. https:\/\/doi.org\/10.3791\/960","DOI":"10.3791\/960"},{"key":"1524_CR20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/01.cji.0000156828.75196.0d","volume":"28","author":"ML Salem","year":"2005","unstructured":"Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)\/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother. 2005;28:220\u20138.","journal-title":"J Immunother"},{"key":"1524_CR21","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1084\/jem.20090247","volume":"206","author":"MP Longhi","year":"2009","unstructured":"Longhi MP, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med. 2009;206:1589\u2013602.","journal-title":"J Exp Med"},{"key":"1524_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.15171\/bi.2018.24","volume":"8","author":"A Mookerjee","year":"2018","unstructured":"Mookerjee A, Graciotti M, Kandalaft LE. A cancer vaccine with dendritic cells differentiated with GM-CSF and IFN\u03b1 and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model. Bioimpacts. 2018;8:211\u201321.","journal-title":"Bioimpacts"},{"key":"1524_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1034\/j.1600-0625.2002.110204.x","volume":"11","author":"A Shibaki","year":"2002","unstructured":"Shibaki A, Katz SI. Induction of skewed Th1\/Th2 T-cell differentiation via subcutaneous immunization with Freund\u2019s adjuvant. Exp Dermatol. 2002;11:126\u201334.","journal-title":"Exp Dermatol"},{"key":"1524_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/30996","volume":"393","author":"SRM Bennett","year":"1998","unstructured":"Bennett SRM, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478.","journal-title":"Nature"},{"key":"1524_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00262-007-0346-8","volume":"57","author":"D Llopiz","year":"2008","unstructured":"Llopiz D, et al. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. Cancer Immunol Immunother. 2008;57:19\u201329.","journal-title":"Cancer Immunol Immunother"},{"key":"1524_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4049\/jimmunol.169.1.117","volume":"169","author":"HH Hofstetter","year":"2002","unstructured":"Hofstetter HH, Shive CL, Forsthuber TG. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund\u2019s adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol. 2002;169:117\u201325.","journal-title":"J Immunol"},{"key":"1524_CR27","doi-asserted-by":"publisher","first-page":"6896","DOI":"10.4049\/jimmunol.177.10.6896","volume":"177","author":"C Fujimoto","year":"2006","unstructured":"Fujimoto C, et al. Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production. J Immunol. 2006;177:6896\u2013903.","journal-title":"J Immunol"},{"key":"1524_CR28","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.4049\/jimmunol.177.3.1552","volume":"177","author":"C Cassan","year":"2006","unstructured":"Cassan C, et al. Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells. J Immunol. 2006;177:1552\u201360.","journal-title":"J Immunol"},{"key":"1524_CR29","doi-asserted-by":"publisher","first-page":"8175","DOI":"10.4049\/jimmunol.178.12.8175","volume":"178","author":"JM Millward","year":"2007","unstructured":"Millward JM, Caruso M, Campbell IL, Gauldie J, Owens T. IFN-\u03b3-induced chemokines synergize with pertussis toxin to promote T cell entry to the central nervous system. J Immunol. 2007;178:8175\u201382.","journal-title":"J Immunol"},{"key":"1524_CR30","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","volume":"73","author":"J Duraiswamy","year":"2013","unstructured":"Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73:3591\u2013603.","journal-title":"Cancer Res"},{"key":"1524_CR31","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"S-R Woo","year":"2012","unstructured":"Woo S-R, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917\u201327.","journal-title":"Cancer Res"},{"key":"1524_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/eji.201545797","volume":"46","author":"NT Joncker","year":"2016","unstructured":"Joncker NT, Bettini S, Boulet D, Guiraud M, Guerder S. The site of tumor development determines immunogenicity via temporal mobilization of antigen-laden dendritic cells in draining lymph nodes. Eur J Immunol. 2016;46:609\u201318.","journal-title":"Eur J Immunol"},{"key":"1524_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.smim.2010.02.004","volume":"22","author":"CL-L Chiang","year":"2010","unstructured":"Chiang CL-L, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol. 2010;22:132\u201343.","journal-title":"Semin Immunol"},{"key":"1524_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/ijc.10777","volume":"103","author":"SR Scheffer","year":"2003","unstructured":"Scheffer SR, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer. 2003;103:205\u201311.","journal-title":"Int J Cancer"},{"key":"1524_CR35","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","volume":"76","author":"KB Chiappinelli","year":"2016","unstructured":"Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016;76:1683\u20139.","journal-title":"Cancer Res"},{"key":"1524_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.trsl.2018.06.003","volume":"204","author":"TR McCaw","year":"2019","unstructured":"McCaw TR, Randall TD, Arend RC. Overcoming immune suppression with epigenetic modification in ovarian cancer. Transl Res. 2019;204:31\u20138.","journal-title":"Transl Res"},{"key":"1524_CR37","doi-asserted-by":"publisher","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","volume":"114","author":"ML Stone","year":"2017","unstructured":"Stone ML, et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A. 2017;114:E10981\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1524_CR38","doi-asserted-by":"publisher","first-page":"44159","DOI":"10.18632\/oncotarget.17395","volume":"8","author":"TB Turner","year":"2017","unstructured":"Turner TB, et al. Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. Oncotarget. 2017;8:44159\u201370.","journal-title":"Oncotarget"},{"key":"1524_CR39","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1365-2990.1997.tb01323.x","volume":"23","author":"B Giometto","year":"1997","unstructured":"Giometto B, et al. Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol. 1997;23:468\u201374.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1524_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1600-0404.2008.01138.x","volume":"120","author":"A Storstein","year":"2009","unstructured":"Storstein A, Krossnes BK, Vedeler CA. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand. 2009;120:64\u20137.","journal-title":"Acta Neurol Scand"},{"key":"1524_CR41","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4049\/jimmunol.167.1.250","volume":"167","author":"SB Su","year":"2001","unstructured":"Su SB, Silver PB, Zhang M, Chan C-C, Caspi RR. Pertussis toxin inhibits induction of tissue-specific autoimmune disease by disrupting G protein-coupled signals. J Immunol. 2001;167:250\u20136.","journal-title":"J Immunol"},{"key":"1524_CR42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nature16939","volume":"530","author":"C Schl\u00e4ger","year":"2016","unstructured":"Schl\u00e4ger C, et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature. 2016;530:349\u201353.","journal-title":"Nature"},{"key":"1524_CR43","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.3390\/ijms22062924","volume":"22","author":"Z Maria","year":"2021","unstructured":"Maria Z, Turner E, Agasing A, Kumar G, Axtell RC. Pertussis toxin inhibits encephalitogenic T-cell infiltration and promotes a B-cell-driven disease during Th17-EAE. Int J Mol Sci. 2021;22:2924.","journal-title":"Int J Mol Sci"},{"key":"1524_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0022-510X(94)90067-1","volume":"127","author":"K Tanaka","year":"1994","unstructured":"Tanaka K, et al. Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J Neurol Sci. 1994;127:153\u20138.","journal-title":"J Neurol Sci"},{"key":"1524_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S0022-510X(98)00257-3","volume":"161","author":"M Tanaka","year":"1998","unstructured":"Tanaka M, Tanaka K, Shinozawa K, Idezuka J, Tsuji S. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci. 1998;161:88\u201390.","journal-title":"J Neurol Sci"},{"key":"1524_CR46","first-page":"2819","volume":"4","author":"AF Carpentier","year":"1998","unstructured":"Carpentier AF, et al. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res. 1998;4:2819\u201324.","journal-title":"Clin Cancer Res"},{"key":"1524_CR47","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/brain\/awh205","volume":"127","author":"H Pellkofer","year":"2004","unstructured":"Pellkofer H, et al. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain. 2004;127:1822\u201330.","journal-title":"Brain"},{"key":"1524_CR48","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00401-014-1351-6","volume":"128","author":"M Schubert","year":"2014","unstructured":"Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol. 2014;128:835\u201352.","journal-title":"Acta Neuropathol"},{"key":"1524_CR49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/nan.12492","volume":"45","author":"D Panja","year":"2019","unstructured":"Panja D, Vedeler CA, Schubert M. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity. Neuropathol Appl Neurobiol. 2019;45:141\u201356.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1524_CR50","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF00309627","volume":"89","author":"JE Greenlee","year":"1995","unstructured":"Greenlee JE, Burns JB, Rose JW, Jaeckle KA, Clawson S. Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption. Acta Neuropathol. 1995;89:341\u20135.","journal-title":"Acta Neuropathol"},{"key":"1524_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0022-510X(91)90198-G","volume":"106","author":"F Graus","year":"1991","unstructured":"Graus F, et al. Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci. 1991;106:82\u20137.","journal-title":"J Neurol Sci"},{"key":"1524_CR52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/0192623316675767","volume":"45","author":"RS Sellers","year":"2017","unstructured":"Sellers RS. Translating mouse models: immune variation and efficacy testing. Toxicol Pathol. 2017;45:134\u201345.","journal-title":"Toxicol Pathol"},{"key":"1524_CR53","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1002\/eji.201444624","volume":"44","author":"NE Blach\u00e8re","year":"2014","unstructured":"Blach\u00e8re NE, et al. T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. Eur J Immunol. 2014;44:3240\u201351.","journal-title":"Eur J Immunol"},{"key":"1524_CR54","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-16-0431","volume":"76","author":"P Tsou","year":"2016","unstructured":"Tsou P, Katayama H, Ostrin EJ, Hanash SM. The emerging role of B cells in tumor immunity. Cancer Res. 2016;76:5597\u2013601.","journal-title":"Cancer Res"},{"key":"1524_CR55","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nri3857","volume":"15","author":"P Shen","year":"2015","unstructured":"Shen P, Fillatreau S. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol. 2015;15:441\u201351.","journal-title":"Nat Rev Immunol"},{"key":"1524_CR56","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.morpho.2017.07.016","volume":"101","author":"M Small","year":"2017","unstructured":"Small M, et al. Specific genetic alterations and tumor immune contexture characterize ovarian tumors with paraneoplastic degeneration and anti-Yo antibodies. Morphologie. 2017;101:245.","journal-title":"Morphologie"},{"key":"1524_CR57","doi-asserted-by":"crossref","unstructured":"Peter E, et al. Immune and genetic signatures of breast carcinomas triggering anti-Yo\u2013associated paraneoplastic cerebellar degeneration. Neurol-Neuroimmunol Neuroinflammation. 2022;9(5):e20001.","DOI":"10.1212\/NXI.0000000000200015"},{"key":"1524_CR58","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11064-013-1204-z","volume":"39","author":"D Lv","year":"2014","unstructured":"Lv D, et al. The similar expression pattern of MHC class I molecules in human and mouse cerebellar cortex. Neurochem Res. 2014;39:180\u20136.","journal-title":"Neurochem Res"},{"key":"1524_CR59","doi-asserted-by":"crossref","unstructured":"Yshii L, et al. IFN-\u03b3 is a therapeutic target in paraneoplastic cerebellar degeneration. JCI Insight. 2019;4(7):e127001.","DOI":"10.1172\/jci.insight.127001"},{"key":"1524_CR60","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1038\/ncomms4633","volume":"5","author":"C Cebri\u00e1n","year":"2014","unstructured":"Cebri\u00e1n C, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun. 2014;5:3633.","journal-title":"Nat Commun"},{"key":"1524_CR61","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/08830180902978120","volume":"28","author":"F Zhou","year":"2009","unstructured":"Zhou F. Molecular mechanisms of IFN-\u03b3 to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol. 2009;28:239\u201360.","journal-title":"Int Rev Immunol"},{"key":"1524_CR62","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1084\/jem.20070064","volume":"204","author":"I Galea","year":"2007","unstructured":"Galea I, et al. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J Exp Med. 2007;204:2023\u201330.","journal-title":"J Exp Med"},{"key":"1524_CR63","doi-asserted-by":"publisher","first-page":"7054","DOI":"10.4049\/jimmunol.169.12.7054","volume":"169","author":"CA Murphy","year":"2002","unstructured":"Murphy CA, Hoek RM, Wiekowski MT, Lira SA, Sedgwick JD. Interactions between hemopoietically derived TNF and central nervous system-resident glial chemokines underlie initiation of autoimmune inflammation in the brain. J Immunol. 2002;169:7054\u201362.","journal-title":"J Immunol"},{"key":"1524_CR64","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1742-2094-11-122","volume":"11","author":"RP Guedes","year":"2014","unstructured":"Guedes RP, et al. A20 deficiency causes spontaneous neuroinflammation in mice. J Neuroinflammation. 2014;11:122.","journal-title":"J Neuroinflammation"},{"key":"1524_CR65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.it.2013.10.005","volume":"35","author":"L Catrysse","year":"2014","unstructured":"Catrysse L, Vereecke L, Beyaert R, van Loo G. A20 in inflammation and autoimmunity. Trends Immunol. 2014;35:22\u201331.","journal-title":"Trends Immunol"},{"key":"1524_CR66","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1042\/BST0391086","volume":"39","author":"L Vereecke","year":"2011","unstructured":"Vereecke L, Beyaert R, van Loo G. Genetic relationships between A20\/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans. 2011;39:1086\u201391.","journal-title":"Biochem Soc Trans"},{"key":"1524_CR67","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nri2527","volume":"9","author":"C M\u00fcnz","year":"2009","unstructured":"M\u00fcnz C, L\u00fcnemann JD, Getts MT, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol. 2009;9:246\u201358.","journal-title":"Nat Rev Immunol"},{"key":"1524_CR68","doi-asserted-by":"crossref","unstructured":"Steinbach K, et al. Brain-resident memory T cells generated early in life predispose to autoimmune disease in mice. Sci Transl Med. 2019;11(498):eaav5519.","DOI":"10.1126\/scitranslmed.aav5519"},{"key":"1524_CR69","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1172\/JCI27372","volume":"116","author":"D Merkler","year":"2006","unstructured":"Merkler D, et al. \u201cViral d\u00e9j\u00e0 vu\u201d elicits organ-specific immune disease independent of reactivity to self. J Clin Invest. 2006;116:1254\u201363.","journal-title":"J Clin Invest"}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-023-01524-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-023-01524-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-023-01524-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T14:06:34Z","timestamp":1708178794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12311-023-01524-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["1524"],"URL":"https:\/\/doi.org\/10.1007\/s12311-023-01524-6","relation":{},"ISSN":["1473-4230"],"issn-type":[{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"20 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}